Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 16/20 | 0.78 |
| ▸ | CTSD | P07339 | 14/20 | 0.78 |
| ▸ | BCHE | P06276 | 1/20 | 0.60 |
| ▸ | CTSB | P07858 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3348617 | 1.00 | BACE1 (0.78) | BACE1CTSDBCHECTSB | |
| SCHEMBL13308306 | 0.88 | BACE1 (0.80) | BACE1CTSDBCHECTSB | |
| SCHEMBL13308305 | 0.88 | BACE1 (0.80) | BACE1CTSDBCHECTSB | |
| SCHEMBL14347997 | 0.88 | BACE1 (0.80) | BACE1CTSDBCHECTSB | |
| SCHEMBL14375076 | 0.88 | BACE1 (0.80) | BACE1CTSDBCHECTSB | |
| SCHEMBL13308307 | 0.88 | BACE1 (0.79) | BACE1CTSDBCHECTSB | |
| SCHEMBL14375056 | 0.88 | BACE1 (0.79) | BACE1CTSDBCHECTSB | |
| SCHEMBL14578010 | 0.88 | BACE1 (1.00) | BACE1CTSDBCHECTSB | |
| SCHEMBL14201569 | 0.88 | BACE1 (1.00) | BACE1CTSDBCHECTSB | |
| SCHEMBL14375055 | 0.88 | BACE1 (0.79) | BACE1CTSDBCHECTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040171881-A1 | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | PHARMACIA & UPJOHN COMPANY | 2004-09-02 | — | — | US | claimed |
| US-7727997-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20070299263-A1 | Hydroxy Alkyl Amines | Elan Pharmaceuticals, Inc. and Pharmacia & Upjohn Company | 2007-12-27 | — | — | US | disclosed |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | ELAN PHARMACEUTICALS, INC. | 2007-09-13 | — | — | US | disclosed |
| US-7176242-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7144897-B2 | Hydroxy alkyl amines | Elan Oharmaceuticals, Inc. (US) | 2006-12-05 | — | — | US | disclosed |
| US-20030166717-A1 | Hydroxy alkyl amines | FRESKOS JOHN (US) | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166717-A1 | Hydroxy alkyl amines | PSEN1, MAOA, PSEN2 | BACE1 47/4885CTSD 3148/4885BCHE 37/4885 |
| US-20040171881-A1 | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | BACE1, BACE2, PSEN1 | BACE1 1/4885CTSD 249/4885BCHE 35/4885 |
| US-20070299263-A1 | Hydroxy Alkyl Amines | MAOA, PSEN2, PSEN1 | BACE1 67/4885CTSD 2851/4885BCHE 20/4885 |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | BACE1, BACE2, APP | BACE1 1/4885CTSD 96/4885BCHE 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.